RLS treatment option discontinued
January 7, 2019
The U.S. Food and Drug Administration recently indicated that GlaxoKlineSmith is discontinuing all dosages of Ropinirole Hydrochloride (Requip) as well as the 2 mg dosage of Ropinirole Hydrochloride (Requip) XL Tablets. Depending on the dosage, these medications will be available through January-May 2019
. This medication is indicated for the treatment of moderate to severe Restless Legs Syndrome as well as Parkinson's disease.